Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination.
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
MRI Mapping of Cerebrovascular Reactivity via Gas Inhalation Challenges.
Soluble adenylyl cyclase is necessary and sufficient to overcome the block of axonal growth by myelin-associated factors.
High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis.
Brain imaging and bladder function.
Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave Dreams Study (Brain Venous Drainage Exploited Against Multiple Sclerosis): study protocol for a randomized controlled trial.
Vitamin D and multiple sclerosis: where do we go from here?
Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1.
Metals and Neurodegeneration.
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.
Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease.
Merck KGaA to try again to get approval for MS pill cladribine
Microparticle Platform
Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.
Association Between CD24-P226-C/T Polymorphism and Multiple Sclerosis: A Meta-Analysis.
Frequency of circulating autoreactive T cells committed to myelin determinants in relapsing-remitting multiple sclerosis patients.
Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.
Dynamic Development of Glucocorticoid Resistance during Autoimmune Neuroinflammation.
Our history
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Fingolimod-Associated Peripheral Vascular Adverse Effects.
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica.
Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.

Pages